SCAI: Ixmyelocel-T studied for dilated cardiomyopathy
(HealthDay) -- For patients with dilated cardiomyopathy, treatment with an autologous bone marrow-derived, expanded multi-cell product, ixmyelocel-T, is well tolerated and associated with improved symptoms at one year, according ...
May 15, 2012
0
0